7.10. guidelines adjuvant therapy tat1 tumours therapy carcinoma situ. general recommendationsstrength ratingcounsel smokers stop smoking.strongthe type therapy transurethral resection bladder (turb) based risk groups shown section 6.3 table 6.1. determination patient’s risk group use 2021 eau risk group calculator available www.nmibc.net.strongin patients tumours presumed low risk small papillary recurrences (presumably ta lg/g1) detected one year previous turb, offer one immediate single chemotherapy instillation.strongoffer post-operative saline water continuous irrigation bladder patients cannot receive single instillation chemotherapy.strongpatients small recurrent low-grade ta tumours effectively safely offered office fulguration.strongonly offer active surveillance selected patients presumed low-grade tumours amendable endoscopic ablation.weakin patients intermediate-risk tumours (with without immediate instillation), offer instillations chemotherapy (the optimal schedule known) one-year full-dose bacillus calmette-guérin (bcg) treatment (induction plus 3-weekly instillations 3, 6 12 months). chemotherapy reasonable first option majority cases; however, final choice made shared decision-making process patient, reflecting his/her risk recurrence progression, well efficacy side effects treatment modality.strongadminister full-dose intravesical bacillus calmette-guérin (bcg) one three years patients high-risk tumours (a complete bcg schedule comprises induction phase six-weekly instillations, followed maintenance phase three-weekly instillations 3, 6, 12, 18, 24, 30 36 months, respectively). additional beneficial effect second third years maintenance weighed added costs, side effects access bcg. immediate radical cystectomy (rc) may also discussed patient.strongdiscuss immediate rc patients high-risk tumours. intravesical full-dose bcg instillations one three years remains option selected patients, particularly decline unfit rc.strongoffer transurethral resection prostate, followed intravesical instillation bcg patients cis epithelial lining prostatic urethra bladder sparing strategy considered.weakcautiously offer quinolones treat bcg-related side effects*.weakthe definition ‘bcg-unresponsive’ respected precisely defines patients unlikely respond bcg instillations.strongoffer rc patients bcg-unresponsive tumours.strongoffer patients bcg-unresponsive tumours, candidates rc due comorbidities, preservation strategies (intravesical chemotherapy, chemotherapy microwave-induced hyperthermia, electromotive administration chemotherapy, intravesical- systemic immunotherapy; preferably within clinical trials).weakdiscuss high-risk high-risk patients within multidisciplinary board, possible.weakrecommendations - technical aspects treatmentintravesical chemotherapyif given, administer single immediate instillation chemotherapy within 24 hours turb.weakomit single immediate instillation chemotherapy case overt suspected bladder perforation bleeding requiring bladder irrigation.strongthe optimal schedule duration intravesical chemotherapy instillation defined; however, exceed one year.weakif intravesical chemotherapy given, use drug optimal ph maintain concentration drug reducing fluid intake instillation.strongthe length individual instillation minimum one, two hours.weakbcg intravesical immunotherapyabsolute contraindications bcg intravesical instillation are:during first two weeks turb;in patients visible haematuria;after traumatic catheterisation;in patients symptomatic urinary tract infection.strong *the side-effect profile quinolones fluoroquinolones resulted adoption european regulation restricting use.